DK1441714T3 - Kombinationer omfattende en selektiv cyclooxygenase-2-inhibitor - Google Patents
Kombinationer omfattende en selektiv cyclooxygenase-2-inhibitorInfo
- Publication number
- DK1441714T3 DK1441714T3 DK02787507T DK02787507T DK1441714T3 DK 1441714 T3 DK1441714 T3 DK 1441714T3 DK 02787507 T DK02787507 T DK 02787507T DK 02787507 T DK02787507 T DK 02787507T DK 1441714 T3 DK1441714 T3 DK 1441714T3
- Authority
- DK
- Denmark
- Prior art keywords
- inhibitor
- combinations
- growth factor
- factor receptor
- receptor tyrosine
- Prior art date
Links
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 title 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 2
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 102000029749 Microtubule Human genes 0.000 abstract 1
- 108091022875 Microtubule Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091008605 VEGF receptors Proteins 0.000 abstract 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008472 epithelial growth Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 210000004688 microtubule Anatomy 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 1
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34473501P | 2001-10-25 | 2001-10-25 | |
| US34473401P | 2001-10-25 | 2001-10-25 | |
| US33603301P | 2001-11-15 | 2001-11-15 | |
| PCT/EP2002/011924 WO2003035047A2 (en) | 2001-10-25 | 2002-10-24 | Combinations comprising a selective cyclooxygenase-2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1441714T3 true DK1441714T3 (da) | 2008-03-31 |
Family
ID=27407094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02787507T DK1441714T3 (da) | 2001-10-25 | 2002-10-24 | Kombinationer omfattende en selektiv cyclooxygenase-2-inhibitor |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20050043409A1 (enExample) |
| EP (1) | EP1441714B1 (enExample) |
| JP (1) | JP2005506366A (enExample) |
| KR (1) | KR100954625B1 (enExample) |
| CN (1) | CN100506224C (enExample) |
| AT (1) | ATE381930T1 (enExample) |
| AU (2) | AU2006252156A1 (enExample) |
| BR (1) | BR0213486A (enExample) |
| CA (1) | CA2464309C (enExample) |
| CY (1) | CY1108045T1 (enExample) |
| DE (1) | DE60224299T2 (enExample) |
| DK (1) | DK1441714T3 (enExample) |
| ES (1) | ES2295428T3 (enExample) |
| HU (1) | HUP0600235A3 (enExample) |
| IL (1) | IL161462A0 (enExample) |
| MX (1) | MXPA04003878A (enExample) |
| NZ (2) | NZ532418A (enExample) |
| PL (1) | PL369305A1 (enExample) |
| PT (1) | PT1441714E (enExample) |
| RU (1) | RU2333754C2 (enExample) |
| SI (1) | SI1441714T1 (enExample) |
| WO (1) | WO2003035047A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0223341D0 (en) * | 2002-10-08 | 2002-11-13 | Groningen Acad Ziekenhuis | Organic compounds |
| WO2005021554A1 (en) | 2003-08-29 | 2005-03-10 | Pfizer Inc. | Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents |
| MXPA06003164A (es) * | 2003-09-23 | 2006-06-05 | Novartis Ag | Combinaciones de un inhibidor del receptor de vegf con otros agentes terapeuticos. |
| JP2007505938A (ja) * | 2003-09-23 | 2007-03-15 | ノバルティス アクチエンゲゼルシャフト | Ｖｅｇｆ受容体阻害剤と化学療法剤の組み合わせ |
| CA2551508C (en) | 2003-12-23 | 2011-08-09 | Pfizer Inc. | Novel quinoline derivatives |
| JO2596B1 (en) * | 2004-11-30 | 2011-02-27 | نوفارتيس ايه جي | Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses |
| EP1982718A4 (en) * | 2006-02-09 | 2010-05-12 | Daiichi Sankyo Co Ltd | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF CANCER |
| EP2065054A1 (en) | 2007-11-29 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Combinations comprising a prostaglandin and uses thereof |
| AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| CN103917236A (zh) | 2011-11-11 | 2014-07-09 | 诺华股份有限公司 | 治疗增生性疾病的方法 |
| MD565Z (ro) * | 2012-05-23 | 2013-07-31 | Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы | Procedeu de tratare a seminţelor de sfeclă de zahăr |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100558356C (zh) * | 1996-10-15 | 2009-11-11 | G.D.瑟尔公司 | 应用环加氧酶-2抑制剂治疗和预防肿瘤形成的方法 |
| US6380394B1 (en) * | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
| CO4960662A1 (es) * | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
| US6025353A (en) * | 1997-11-19 | 2000-02-15 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents |
| US6887893B1 (en) * | 1997-12-24 | 2005-05-03 | Sankyo Company, Limited | Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia |
| CA2356462A1 (en) * | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| IL147913A0 (en) * | 1999-08-12 | 2002-08-14 | American Cyanamid Co | Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer |
| CA2392931A1 (en) * | 1999-12-03 | 2001-06-07 | Pfizer Products Inc. | Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents |
| ITMI992711A1 (it) * | 1999-12-27 | 2001-06-27 | Novartis Ag | Composti organici |
| WO2001060365A1 (en) * | 2000-02-17 | 2001-08-23 | Merck & Co., Inc. | Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
| EP1259236A4 (en) * | 2000-02-25 | 2004-11-03 | Merck & Co Inc | Tyrosine kinase inhibitors |
| WO2001064669A1 (en) * | 2000-03-03 | 2001-09-07 | Pfizer Products Inc. | Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
-
2002
- 2002-10-24 DE DE60224299T patent/DE60224299T2/de not_active Expired - Lifetime
- 2002-10-24 JP JP2003537614A patent/JP2005506366A/ja active Pending
- 2002-10-24 AT AT02787507T patent/ATE381930T1/de active
- 2002-10-24 EP EP02787507A patent/EP1441714B1/en not_active Expired - Lifetime
- 2002-10-24 PT PT02787507T patent/PT1441714E/pt unknown
- 2002-10-24 RU RU2004116069/15A patent/RU2333754C2/ru not_active IP Right Cessation
- 2002-10-24 KR KR1020047006101A patent/KR100954625B1/ko not_active Expired - Fee Related
- 2002-10-24 CA CA2464309A patent/CA2464309C/en not_active Expired - Fee Related
- 2002-10-24 NZ NZ532418A patent/NZ532418A/en not_active IP Right Cessation
- 2002-10-24 SI SI200230672T patent/SI1441714T1/sl unknown
- 2002-10-24 ES ES02787507T patent/ES2295428T3/es not_active Expired - Lifetime
- 2002-10-24 CN CNB028211375A patent/CN100506224C/zh not_active Expired - Fee Related
- 2002-10-24 HU HU0600235A patent/HUP0600235A3/hu unknown
- 2002-10-24 IL IL16146202A patent/IL161462A0/xx unknown
- 2002-10-24 NZ NZ552335A patent/NZ552335A/en not_active IP Right Cessation
- 2002-10-24 BR BR0213486-1A patent/BR0213486A/pt active Search and Examination
- 2002-10-24 PL PL02369305A patent/PL369305A1/xx not_active Application Discontinuation
- 2002-10-24 MX MXPA04003878A patent/MXPA04003878A/es active IP Right Grant
- 2002-10-24 WO PCT/EP2002/011924 patent/WO2003035047A2/en not_active Ceased
- 2002-10-24 DK DK02787507T patent/DK1441714T3/da active
- 2002-10-24 US US10/493,297 patent/US20050043409A1/en not_active Abandoned
-
2006
- 2006-12-20 AU AU2006252156A patent/AU2006252156A1/en not_active Abandoned
-
2008
- 2008-02-18 CY CY20081100197T patent/CY1108045T1/el unknown
-
2010
- 2010-02-08 AU AU2010200433A patent/AU2010200433A1/en not_active Abandoned
- 2010-11-03 US US12/938,868 patent/US20110046190A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR100954625B1 (ko) | 2010-04-27 |
| CA2464309C (en) | 2012-01-03 |
| AU2010200433A1 (en) | 2010-02-25 |
| PL369305A1 (en) | 2005-04-18 |
| CN100506224C (zh) | 2009-07-01 |
| US20050043409A1 (en) | 2005-02-24 |
| WO2003035047A2 (en) | 2003-05-01 |
| BR0213486A (pt) | 2005-05-10 |
| NZ552335A (en) | 2008-11-28 |
| ATE381930T1 (de) | 2008-01-15 |
| EP1441714A2 (en) | 2004-08-04 |
| KR20040048992A (ko) | 2004-06-10 |
| SI1441714T1 (sl) | 2008-06-30 |
| JP2005506366A (ja) | 2005-03-03 |
| EP1441714B1 (en) | 2007-12-26 |
| WO2003035047A3 (en) | 2003-10-23 |
| HK1068261A1 (en) | 2005-04-29 |
| HUP0600235A3 (en) | 2008-04-28 |
| RU2333754C2 (ru) | 2008-09-20 |
| DE60224299D1 (de) | 2008-02-07 |
| IL161462A0 (en) | 2004-09-27 |
| RU2004116069A (ru) | 2005-06-10 |
| ES2295428T3 (es) | 2008-04-16 |
| AU2006252156A1 (en) | 2007-01-18 |
| PT1441714E (pt) | 2008-03-10 |
| HUP0600235A2 (en) | 2007-02-28 |
| MXPA04003878A (es) | 2004-07-08 |
| NZ532418A (en) | 2007-02-23 |
| CN1575168A (zh) | 2005-02-02 |
| CY1108045T1 (el) | 2013-09-04 |
| US20110046190A1 (en) | 2011-02-24 |
| CA2464309A1 (en) | 2003-05-01 |
| DE60224299T2 (de) | 2008-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE300529T1 (de) | Imidazolderivate als raf-kinase-inhibitoren | |
| NO20044475L (no) | 2-(2,6-diklorfenyl)-diarulimidazoler | |
| MY169308A (en) | Treatment of tnf? related disorders | |
| GB0121490D0 (en) | Ciompounds | |
| CY1108045T1 (el) | Συνδυασμοι που περιλαμβανουν εναν επιλεκτο αναστολεα της κυκλοοξυγενασης-2 | |
| ATE442142T1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
| DE50310516D1 (de) | Fredericamycin-derivate | |
| WO2001062784A3 (en) | Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer | |
| GB0121494D0 (en) | Compounds | |
| AU3919001A (en) | Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers | |
| DE60131968D1 (de) | PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN | |
| DE50211672D1 (de) | Urokinase-inhibitoren | |
| NO20040973L (no) | Anvendelse av 4-pyridylmetylftalaziner for kreftbehandling | |
| ATE423780T1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
| ATE400268T1 (de) | Bisindolylmaleimid zur behandlung von prostatakrebs und akt-vermittelten erkrankungen | |
| ATE373661T1 (de) | 1.3.4-triaza-phenalen- und 1,3,4,6- tetraazaphenalen-derivative | |
| DE60120398D1 (de) | Imidazopyridin-8-one | |
| BG108033A (bg) | Използване на 2-амино-1-(4-хидрокси-2-метансулфонамидофенил) етанол за лечение на инконтиненция | |
| UA49216A (uk) | Засіб для лікування ускладнень після видалення злоякісних новоутворень шкіри | |
| WO2004044226A3 (en) | Induction of cellular senescence by cdk4 disruption for tumor supression and regression | |
| ATE297745T1 (de) | Chemische modifizierung von harn von säugern | |
| UA40408A (uk) | Спосіб комбінованого лікування раку щитовидної залози | |
| MXPA04002407A (es) | Uso de 4-piridilmeetil-ftalazinas para el tratamiento de cancer. |